Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

Inclusion Criteria: * Provide written informed consent * be between 18 and 65 years at the time of signing the Informed Consent * have a clinical diagnosis of asthma prior to screening in accordance with the guidelines of the American Thoracic Society/European Respiratory Society * ACQ over 1.25 * have a smoking history of less than 10 pack-years total and have not been smoking for at least the last 12 months * Perform a positive methacholine challenge at screening and repeat positive methacholine challenge at baseline visit (14 days later) * Have normal or mild obstructive spirometry * Have normal right heart function as documented by Doppler echo or right heart catheterization * If female, be surgically sterile, post-menopausal (more than 1 year), or practice double barrier methods of birth control * Subjects may receive non-drug therapies including oxygen supplementation no greater than 2L/minute, and pulmonary rehabilitation * Subjects may be on standard of care asthma medications including inhaled corticosteroids-long acting beta agonist at a dose not greater than 1 mg of a fluticasone equivalent Exclusion Criteria: * Have any active infection that is not treated * Be unable to perform any of the assessments required for endpoint analysis. * currently receive (or have received within four weeks of screening) experimental agents for the treatment of asthma * be actively listed (or expecting to be listed in the near future) for transplant of any organ * Have clinically important abnormal screening laboratory values : blood screening tests (Hematology, Chemistry, CBC including Eosinophil count) results that are not within normal limits (according to UMHC Laboratory Reference Ranges) Have a serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study * Have known allergies to penicillin or streptomycin * Be an organ transplant recipient * Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma * Have a non-pulmonary condition that limits lifespan to less than a year. * Have a history of drug or alcohol abuse within the past 24 months. * Be serum positive for HIV, hepatitis BsAg or Viremia hepatitis C * Be currently participating (or have participated within the previous 30 days) in an investigational therapeutic or device trial. * Have hypersensitivity to dimethyl sulfoxide (DMSO) * Have a resting oxygen saturation (SpO2) on room air of more than 93% at sea level or more than 88% at an altitude above 5,000 feet above sea level (1524 meters)